Company intelligence / Profile preview

Shanghai Aizhiwei Health Technology

Shanghai, Shanghai, Chinachictr.org.cn ↗

Ownership: Private
Development stage: Commercial

Overview

Shanghai Aizhiwei Health Technology is a subsidiary of Eddard Biology (300685.SZ). In 2022, Eddard Biology announced the proposed sale of 80% of its holding in Shanghai Aizhiwei Health Technology, indicating a change in ownership structure. The company appears to be involved in healthcare technology and/or biotech, but specific clinical results or product details are not disclosed publicly.

Therapeutic areas: Other
Modalities: Diagnostic technologiesHealth-related devices
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Shanghai Aizhiwei Health Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Aizhiwei Health Technology.

Explore the full profile